NCT00351871View on ClinicalTrials.gov

Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy

PHASE4CompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Chronic Hepatitis C

Interventions

DRUG

PEG-Intron Plus REBETOL

Sponsors

Collaborators (1)

Schering-Plough

All Listed Sponsors

collaborator

Schering-Plough

INDUSTRY

lead

Louisiana State University Health Sciences Center in New Orleans

OTHER